CD19 and lymphoma: It is noteworthy that a clinical trial investigating product‐derived lymphoma following infusion of piggyBac‐modified CD19 CAR‐T cells yielded negative results.[55] One patient developed CAR T‐cell‐derived lymphoma, and unfortunately, another patient died.